Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Viatris to make $1.65B Pacira acquisition, adding to momentum in pain

Viatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences. The Thursday morning deal, valued at $1.65 billion, follows a ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Also reported by 2 other outlets

Read the original at endpoints.news →

More in Health & Medicine

More from Thursday 8 October →